Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zimmer Biomet Holdings Q3 2026 Results: Net Income $192M, Down 17.0% YoY

For the nine months ended September 30, 2026, Zimmer Biomet reported net sales of $6,326.6 million, a 5.7% increase over the prior year, and net earnings of $630.9 million. The company experienced higher selling, general, and administrative expenses but saw an improvement in operating profit from $943.6 million to $1,006.8 million year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2,062.92,001.4
Profit before tax230.1279.2
Net income191.6230.9
EPS (diluted, $ a share)$1.00$1.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-17.0%
Revenue, year on year+3.1%
Operating margin14.9%
Source

10-Q filed with the SEC, NYSE: ZBH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zimmer Biomet Holdings, Inc.: key numbers

Share price
$101.41Close, Nov 16
Market cap
$19.2B
Shares outstanding
189.25MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zimmer Biomet Holdings, Inc.

All →
4:07 PM ET 8-K
Loan & Debt

Zimmer Biomet Holdings $500M Debt Financing with Barclays Capital Inc.

Zimmer Biomet Holdings, Inc. completed a dual-currency public offering of senior notes, consisting of $500 million of 5.850% notes due 2036 and €500 million of 4.375% notes due 2033. The proceeds are intended to be used for general corporate purposes, which may include the repayment of existing 2.425% notes due 2026 and 4.700% notes due 2027.

Value
$500M
Counterparty
Barclays Capital Inc.
Term
through 2036
6:31 AM ET 8-K
Financial Results

Zimmer Biomet Holdings Financial Results

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, a 3.1% increase over the prior year, driven by strong performance in its Hips, S.E.T., and Technology & Data franchises. The company updated its full-year 2026 guidance, raising its organic constant-currency sales growth and adjusted EPS targets based on solid commercial execution.

Term
Q3 2026

“We are very pleased with our solid third quarter results, growing net sales 3.7% on a constant-currency basis and generating strong operating and free cash flow. Our Hips, S.E.T. and Technology & Data, Bone Cement and Surgical franchises – representing two-thirds of our book of business – grew at upper single digit or double-digit rates, validating the progress of our diversification strategy, the strength of our innovation engine and the significant strides we are making in commercial execution.”

Ivan Tornos, Chairman, President and CEO of Zimmer Biomet

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.